The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma
Abstract
Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours. Standard treatment is surgical resection. Following complete resection of the primary tumour, patients with PPGL are at risk of developing new tumoural events. The present guideline aims to propose standardised clinical care of long-term follow-up in patients operated on for a PPGL. The guideline has been developed by The European Society of Endocrinology and based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) principles. We performed a systematic review of the literature and analysed the European Network for the Study of Adrenal Tumours (ENS@T) database. The risk of new events persisted in the long term and was higher for patients with genetic or syndromic diseases. Follow-up in the published cohorts and in the ENS@T database was neither standardised nor exhaustive, resulting in a risk of follow-up bias and in low statistical power beyond 10 years after complete surgery. To inform patients and care providers in this context of low-quality evidence, the Guideline Working Group therefore prepared recommendations on the basis of expert consensus. Key recommendations are the following: we recommend that all patients with PPGL be considered for genetic testing; we recommend assaying plasma or urinary metanephrines every year to screen for local or metastatic recurrences or new tumours; and we suggest follow-up for at least 10 years in all patients operated on for a PPGL. High-risk patients (young patients and those with a genetic disease, a large tumour and/or a paraganglioma) should be offered lifelong annual follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1498 · Cited by 2,827
Self-citationMutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.
Gimenez‐Roqueplo, A., Favier, J., Rustin, P., Rieubland, C., Crespin, M., Nau, V., Kien, P. K. V., Corvol, P. L., Plouin, P., & Jeunemaître, X. (2003) · PubMed · Cited by 609
Self-citationChen, H., Sippel, R. S., O'Dorisio, M. S., Vinik, A. I., Lloyd, R. V., & Pacak, K. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb4f0 · Cited by 593
Paraganglioma and phaeochromocytoma: from genetics to personalized medicine
Favier, J., Amar, L., & Gimenez-Roqueplo, A.-P. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.188 · Cited by 490
Self-citationAmar, L., Baudin, E., Burnichon, N., Peyrard, S., Silvera, S., Bertherat, J., Bertagna, X., Schlumberger, M., Jeunemaitre, X., Gimenez-Roqueplo, A.-P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0709 · Cited by 450
Self-citationPathological grading for predicting metastasis in phaeochromocytoma and paraganglioma
Kimura, N., Takayanagi, R., Takizawa, N., Itagaki, E., Katabami, T., Kakoi, N., Rakugi, H., Ikeda, Y., Tanabe, A., Nigawara, T., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0494 · Cited by 393
Eisenhofer, G., Lenders, J. W. M., Siegert, G., Bornstein, S. R., Friberg, P., Milosevic, D., Mannelli, M., Linehan, W. M., Adams, K., Timmers, H. J., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.07.016 · Cited by 334
Self-citationThe diagnosis and management of malignant phaeochromocytoma and paraganglioma
Chrisoulidou, A., Kaltsas, G., Ilias, I., & Grossman, A. B. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0074 · Cited by 314
Dixon, R. (2007) · Routledge eBooks · doi:10.4324/9780080518916 · Cited by 249
Whole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene
Cascón, A., Comino-Méndez, I., Currás-Freixes, M., de Cubas, A. A., Contreras, L., Richter, S., Peitzsch, M., Mancikova, V., Inglada-Pérez, L., Pérez-Barrios, A., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv053 · Cited by 192
Laboratory Evaluation of Pheochromocytoma and Paraganglioma
Eisenhofer, G., & Peitzsch, M. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.224832 · Cited by 187
Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score
Wu, D., Tischler, A. S., Lloyd, R. V., DeLellis, R. A., de Krijger, R., van Nederveen, F., & Nosé, V. (2009) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318190d12e · Cited by 175
Gimenez-Roqueplo, A.-P., Caumont-Prim, A., Houzard, C., Hignette, C., Hernigou, A., Halimi, P., Niccoli, P., Leboulleux, S., Amar, L., Borson-Chazot, F., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2975 · Cited by 159
Self-citationAsari, R., Scheuba, C., Kaczirek, K., & Niederle, B. (2006) · Archives of Surgery · doi:10.1001/archsurg.141.12.1199 · Cited by 125
Pheochromocytoma in Pregnancy: A Case Series and Review
Oliva, R., Angelos, P., Kaplan, E. L., & Bakris, G. L. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.147579 · Cited by 119
Observer Variation in the Application of the Pheochromocytoma of the Adrenal Gland Scaled Score
Raab, S. S. (2013) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/j.ypat.2012.11.007 · Cited by 114
Malignant Pheochromocytoma: Chromaffin Granule Transmitters and Response to Treatment
Rao, F., Keiser, H. R., & O’Connor, D. T. (2000) · Hypertension · doi:10.1161/01.hyp.36.6.1045 · Cited by 99
Amar, L., Faßnacht, M., Gimenez‐Roqueplo, A., Januszewicz, A., Prejbisz, A., Timmers, H. J. L. M., & Plouin, P. (2012) · Hormone and Metabolic Research · doi:10.1055/s-0031-1301339 · Cited by 82
Self-citationAmar, L., Lussey‐Lepoutre, C., Lenders, J. W. M., Djadi‐Prat, J., Plouin, P., & Steichen, O. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0189 · Cited by 81
Self-citationThe management of head-and-neck paragangliomas
Capatina, C. A.-M., Ntali, G., Karavitaki, N., & Grossman, A. B. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0223 · Cited by 79
Clinical utility of chromogranin A in SDH x‐related paragangliomas
Zuber, S. M., WESLEY, R. A., Prodanov, T., Eisenhofer, G., Pacák, K., & Kantorovich, V. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12245 · Cited by 45
Peritoneal Implantation of Pheochromocytoma Following Tumor Capsule Rupture During Surgery
Rafat, C., Zinzindohoué, F., Hernigou, A., Hignette, C., Favier, J., Tenenbaum, F., Gimenez‐Roqueplo, A., Plouin, P., & Amar, L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1975 · Cited by 43
Self-citationDekkers, O. M., Burman, P., & _, _. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0625 · Cited by 9
Self-citationAvoiding and Nonexpressing: Coping Styles of Patients With Paragangliomas
van Hulsteijn, L. T., Kaptein, A. A., Louisse, A., Smit, J. W. A., & Corssmit, E. P. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1340 · Cited by 5
Cited by
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
Olsen, M. H., Angell, S. Y., Asma, S., Boutouyrie, P., Burger, D., Chirinos, J. A., Damasceno, A., Delles, C., Gimenez-Roqueplo, A.-P., Hering, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31134-5 · Cited by 939
Self-citationNeuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E., Blaszkowsky, L. S., Brock, P., Chan, J., Das, S., Dickson, P. V., Fanta, P., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0032 · Cited by 619
Fassnacht, M., Assie, G., Baudin, E., Eisenhofer, G., de la Fouchardiere, C., Haak, H. R., de Krijger, R., Porpiglia, F., Terzolo, M., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2099 · Cited by 436
Self-citation
Metadata
- Authors
- Plouin, P. F., Amar, L., Dekkers, O. M., Fassnacht, M., Gimenez-Roqueplo, A. P., Lenders, J. W. M., Lussey-Lepoutre, C., Steichen, O., & _, _.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-05
- Volume
- 174
- Issue
- 5
- Pages
- G1-G10
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2333098768
- Cited by
- 480
- References
- 27
- FWCI
- 41.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.